The IL-33/ST2 axis was initially evaluated in relation to the ability to influence neoplastic growth, and later in relation to cardiovascular diseases, inflammatory conditions, fibroproliferative diseases, autoimmune diseases, and systemic infections. The gene discussed is IL33; the disease is autoimmune disease.